Core Viewpoint - In the first half of 2025, the company Inco Medical achieved significant revenue growth despite challenges from international situations and tariffs, with a revenue of 4.913 billion yuan, up 8.9% year-on-year, and a net profit of 710 million yuan, up 21.02% year-on-year [1] Group 1: Industry Overview - The global disposable glove industry has undergone significant changes, with Malaysia dominating the supply before 2019, followed by accelerated production expansion by Chinese companies from 2020 to 2021, leading to a shift in competitive dynamics [1] - The industry faced severe competition and price drops to historical lows from 2022 to 2023 due to supply-demand imbalances, but signs of recovery and improved capacity utilization were noted in 2024 [1] Group 2: Company Performance - In the first half of 2025, the company maintained full production and sales while significantly increasing its development efforts in non-U.S. markets, resulting in a 45% year-on-year increase in overseas non-U.S. market sales and a 35% increase in domestic market sales [1] - The company has established a leading global manufacturing capability with an annual production capacity of 87 billion gloves, including 56 billion nitrile gloves and 31 billion PVC gloves, supported by advanced automated production lines and intelligent control systems [2] Group 3: Future Initiatives - The company is steadily advancing the construction of overseas production bases, enhancing its global supply chain layout to support business globalization [2] - In terms of green development, the company initiated a wind power project in Anhui in 2024, aiming for completion and operation in 2025, which will increase the share of clean energy in its overall energy structure [2] - The company plans to integrate green energy with medical production to promote sustainable development in the industry [2]

英科医疗科技股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 单位： 人民币万元 | 非经营性资金占用 | 资金占 用方名 | 占用方与上市 公司的关联关 | 上市公司核 算的会计科 | 年期初占 2025 | 2025 | 上半年占用累计 发生金额（不含利 | 上半年偿还 2025 | 上半年占 2025 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 用资金余额 | | | 累计发生金额 | 用资金余额 | 原因 | | | | 称 | 系 | 目 | | | 息） | | | | | | 控股股东、实际控 制人及其附属企业 | | | | | | 不适用 | | | | | | 小 计 | | | | | | 不适用 | | | | | | 前控股股东、实际 控制人及其附属企 | | | | | | 不适用 | | | | | | 业 | | | | | | | | | | | | 小 计 | | | | | | 不适用 | | | | ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-119 英科医疗科技股份有限公司 为使投资者全面了解报告期内公司的经营情况和财务状况，公司 《2025 年半年度报告》全文及摘要将于 2025 年 8 月 29 日在巨潮资 讯网（www.cninfo.com.cn）披露，敬请投资者注意查阅。 特此公告。 英科医疗科技股份有限公司 董 事 会 2025 年 8 月 29 日 2025 年半年度报告披露提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 28 日召开第四届董事会第八次（定期）会议，审议通过了《关于 <2025 年半年度报告>及其摘要的议案》。该议案已经公司第四届董事 会审计委员会第五次会议审议通过。 ...

Core Insights - The company reported a revenue of 4.913 billion yuan for the first half of 2025, representing a year-on-year growth of 8.9% [1] - The net profit attributable to shareholders reached 710 million yuan, showing a year-on-year increase of 21.02% [1] Company Overview - The company is a comprehensive medical care product supplier based in China, with main business segments including personal protection, rehabilitation care, and other products [1] - Key products include disposable gloves, wheelchairs, hot and cold packs, and electrode pads, which are widely used in medical institutions, elderly care facilities, daily consumer use, and other related industries [1] Rehabilitation Care Products - The company's rehabilitation care products fall under the category of assistive walking devices, which include electric wheelchairs, manual wheelchairs, walkers, walking aids, canes, and medical bedside tables [1] - These products serve as mobility aids for individuals with physical disabilities, the elderly, and those with limited mobility, facilitating walking, hospital care, and daily assistance for disabled individuals [1]

证券代码：300677 证券简称：英科医疗 公告编号：2025-118 英科医疗科技股份有限公司 第四届董事会第八次（定期）会议决议公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 英科医疗科技股份有限公司（以下简称"公司"）第四届董事会 第八次（定期）会议于 2025 年 8 月 28 日在公司会议室以现场会议结 合通讯方式召开，会议通知已于 2025 年 8 月 18 日以专人送达、电子 邮件、传真、电话或即时通讯工具等形式向全体董事发出。会议由公 司董事长刘方毅先生召集并主持，本次会议应出席董事 9 名，实际出 席会议董事 9 名，公司部分高级管理人员列席了本次会议。会议的召 集和召开符合《中华人民共和国公司法》《英科医疗科技股份有限公 司章程》（以下简称"《公司章程》"）的有关规定。 二、董事会会议审议情况 1、审议通过《关于<2025年半年度报告>及其摘要的议案》 董事会认为《2025 年半年度报告》及其摘要的内容真实、准确 和完整，没有虚假记载、误导性陈述或者重大遗漏。 具体内容请详见同日登载于巨潮资讯网（www.cninfo ...

证券代码：300677 证券简称：英科医疗 公告编号：2025-121 英科医疗科技股份有限公司 为进一步落实国家关于鼓励上市公司现金分红的政策，综合考虑 投资者的回报需求和公司的长远发展，在保证正常经营和业务发展的 前提下，公司拟定 2025 年半年度利润分配预案如下： 拟以公司权益分派实施时股权登记日总股本扣除公司回购专户 上已回购股份后的总股本为基数，向全体股东每 10 股派发现金股利 人民币 0.5 元（含税），不送红股，不转增股本。以截至 2025 年 8 月18日的公司总股本654,793,743股扣除公司回购专户上已回购股份 2,703,400 股后的总股本 652,090,343 股测算，初步核算拟分配的现金 红利总额约为人民币 3,260.45 万元（含税），预计占 2025 年半年度 归属于上市公司股东净利润的比例为 4.59%。 如在利润分配预案披露至实施该方案的股权登记日期间，享有利 润分配权的股本总数发生变动，公司将按照每股分配现金股利金额不 变的原则对分配总额进行调整。 关于 2025 年半年度利润分配预案的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、 ...

Core Viewpoint - In the first half of the year, the company reported a revenue of 4.913 billion yuan, reflecting a year-on-year growth of 8.90%, and a net profit attributable to shareholders of 710 million yuan, which represents a year-on-year increase of 21.02% [1] Financial Performance - The company's operating revenue for the first half of the year was 4.913 billion yuan, marking an 8.90% increase compared to the same period last year [1] - The net profit attributable to shareholders reached 710 million yuan, showing a growth of 21.02% year-on-year [1] - Basic earnings per share were reported at 1.12 yuan [1]

Core Viewpoint - The company reported a revenue of 4.913 billion yuan for the first half of 2025, reflecting a year-on-year growth of 8.90% and a net profit of 710 million yuan, which represents a year-on-year increase of 21.02% [1] Financial Performance - Revenue for the first half of 2025 reached 4.913 billion yuan, marking an 8.90% increase compared to the previous year [1] - Net profit for the same period was 710 million yuan, showing a growth of 21.02% year-on-year [1] Profit Distribution Plan - The board of directors approved a profit distribution plan, proposing a cash dividend of 0.5 yuan (including tax) for every 10 shares to all shareholders [1] - No bonus shares will be issued, and there will be no capital reserve fund conversion into share capital [1]

Financial Performance - Revenue for the reporting period reached ¥4,913,439,043.41, an increase of 8.90% compared to ¥4,512,068,808.00 from the same period last year[25]. - Net profit attributable to shareholders was ¥710,439,983.93, reflecting a growth of 21.02% from ¥587,027,351.00 year-over-year[25]. - The net cash flow from operating activities surged by 170.15% to ¥745,482,560.58, compared to ¥275,947,372.00 in the previous year[25]. - Basic and diluted earnings per share increased by 24.44% to ¥1.12, up from ¥0.90[25]. - Total assets at the end of the reporting period amounted to ¥39,515,486,044.55, representing a 14.10% increase from ¥34,630,896,412.44 at the end of the previous year[25]. - The gross profit margin for personal protective products increased by 2.60% to 24.47%, with revenue growth of 9.31% year-on-year[88]. - The company achieved a total R&D expenditure of RMB 203,842,179.90, with an R&D expense ratio of 4.15%[67]. - The company reported a significant increase in production capacity, aiming to meet the growing market demand for its medical products[159]. Market Expansion and Strategy - In the first half of 2025, overseas non-US market sales revenue increased by approximately 45% year-on-year, while domestic market sales revenue grew by about 35%[7]. - The company is actively implementing a global supply chain strategy and expanding overseas production capacity to reduce reliance on the U.S. market[59]. - The company is focused on expanding its leadership in the disposable glove industry, aiming to become the most competitive player in the personal protective equipment sector globally[33]. - The company plans to enhance its manufacturing capabilities through automation and smart production equipment upgrades by 2025[63]. - The company is exploring potential mergers and acquisitions to enhance its market position and diversify its product offerings[160]. - The company plans to expand its market presence through strategic acquisitions and partnerships, aiming to enhance its competitive edge in the healthcare industry[159]. - The company is committed to investing in research and development to drive technological advancements in its product lines, ensuring long-term sustainability and growth[159]. Product Development and Innovation - The company plans to launch two new products, Eco economic iron wheelchair and Move-F walker, in the first half of 2025, while upgrading existing products like bedside tables and manual/electric wheelchairs[64]. - The company is actively pursuing new product development in the medical technology sector, with a focus on innovative healthcare solutions[159]. - The company is focusing on the development of new medical products, with a projected investment of 20,000 million in research and development over the next two years[160]. - The company has successfully launched three new medical devices in the last quarter, contributing to a 15% increase in market share[160]. Risk Management and Compliance - The company faces uncertainties due to geopolitical factors affecting tariffs, which could impact overall operational performance[7]. - The company has highlighted the importance of risk awareness regarding its future plans, which depend on various factors including national policies and market demand[5]. - The company has ongoing management and financial control measures in place to mitigate risks associated with its overseas operations[92]. - The company maintains strict compliance with laws and regulations to protect the rights of shareholders and creditors, ensuring transparent information disclosure[130][131]. Shareholder and Dividend Information - The profit distribution plan approved by the board of directors includes a cash dividend of 0.5 RMB per 10 shares (tax included) and no bonus shares[8]. - A cash dividend of 0.50 RMB per share (before tax) is proposed, with a total cash dividend amounting to approximately 32.6 million RMB, representing 100% of the distributable profit[124]. - The company plans to distribute a cash dividend of ¥0.8 per share (before tax) to all shareholders based on the total share capital after the buyback[200]. - The company intends to distribute a cash dividend of ¥1 per share (before tax) to all shareholders in June 2025, based on the total share capital after the buyback[200]. Environmental and Social Responsibility - The company has established a robust supply chain management system to enhance supplier ESG risk management and improve supply chain resilience[134]. - The company actively engages in social responsibility initiatives, including poverty alleviation activities and support for students during exam periods[135]. - The company has included 7 subsidiaries in the legally mandated environmental information disclosure list, demonstrating its commitment to environmental responsibility[128]. Operational Efficiency and Technology - The company emphasizes the transformation of its manufacturing system towards automation and green development, significantly enhancing production and operational efficiency[7]. - The company maintains a production technology advantage with a product yield rate consistently above 99%[63]. - The company is focused on enhancing operational efficiency through the implementation of new technologies and processes, which is expected to improve profit margins[159].

证券代码：300677 证券简称：英科医疗 公告编号：2025-117 关于为子公司提供担保事项的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日、2025 年 5 月 26 日分别召开的第四届董事会第二次（定期） 会议、第四届监事会第二次（定期）会议以及 2024 年度股东大会， 审议通过了《关于公司及子公司向银行申请授信额度及担保事项的议 案》。为满足公司及子公司的生产经营需要，公司及子公司拟向银行 等金融机构申请综合授信的额度以及金融衍生品交易风险限额的总 额（以下简称"授信额度"）不超过 360 亿元人民币，对其担保总额 不超过 360 亿元人民币，授权期限自公司 2024 年度股东大会审议通 过之日起至下一年度股东大会召开时止。具体内容详见刊登于巨潮资 讯网（www.cninfo.com.cn）的《关于公司及子公司向银行申请授信额 度及担保事项的公告》《2024 年度股东大会决议公告》（公告编号： 2025-046、2025-072）。 一、担保事项概述 英科医疗科技股 ...